Profit before tax jumped 64% to Rs. 226 crore, while the company maintained robust investment in innovation with net R&D spend of Rs. 249 crore
Occlutech develops, manufactures, and commercialises medical devices for congenital heart disease, stroke prevention, and heart failure
The pharmaceutical segment led growth, generating Rs. 337 crore in revenue, while the crop protection business contributed Rs. 157 crore
The company reported profit before tax of Rs.67 crore, up sharply from Rs.21 crore in the same period last year
Revenue from operations surged 30% year-on-year to Rs. 68,645 million
Launched in August 2025, GSK India’s Oncology business is rapidly gaining momentum
The therapy is currently completing Phase 1 clinical trials in renal cell carcinoma and non-small cell lung cancer
These results were consistent across all clinically relevant patient subgroups regardless of key patient characteristics like age or sex, the cause of stroke or the severity of the stroke
Subscribe To Our Newsletter & Stay Updated
